User Guide Medtech32

New Zealand Formulary (BPACNZRx) Integration



(February 2020)



These release notes contain important information for Medtech32 users. Please ensure that they are circulated amongst all relevant staff. We suggest that this document is filed safely for future reference.

Contents

What is BPACNZRx?	4
Restrictions of the BPACNZRx solution	5
Pregnancy warnings are displayed regardless of age	5
NO ABILITY TO SUPPRESS DRUGS 'AT RISK WHEN PREGNANT'	5
Extention of Medical Warnings to allow 'Other Substance' allergies to be recorded	5
No cross-sensitivity checks	6
Price may be incorrectly displayed	6
Activation of BPACNZRX is at Database Level not Practice Level	6
Registration for activation of BPACNZRx	_7
Activation of BPACNZRx	8
Activating the BPACNZRX NZF integration for the first time	8
Switching from BPACNZRx back to MIMS	12
Monthly Drug Updates	<u>13</u>
Drug Setup	<u>15</u>
Drug Class and Therapeutic Options	15
NZULM CODING	15
IMMP and Sport Categories	16
Staff Setup	18
Enable Repeat Script without Old Drug Warnings	18
DISPLAY WARNING FOR MILD PATIENT MEDICAL WARNINGS	18
Interaction Warning Messages	19
Action based Interactions	19
Severity based Interactions	20
Evidence based Interactions	21
Medical Warnings	<u>22</u>
Mapping MIMS Medical Warnings to NZF Medical Warnings	22
Steps to remap a Medical Warning	23
CREATING A NEW MEDICAL WARNING	31
Medication and Other Substance Predictive Searches	32
Patient Medications	<u>38</u>

medtech®

MAPPING MIMS MEDICATIONS TO NZF MEDICATIONS	38
Steps to remap a Medication record when selected for repeating	39
NEW PATIENT MEDICATION	43
NZF Drug Terms	44
BPACNZRX LOGO	45
Drug Search	46
Section 29 Drugs	50
Monographs	51
INTERACTIONS	53
Personal, Preferred and User-Defined Drugs	55
Personal Medicines	55
Preferred Medication	55
User-Defined Drugs	55
Reports	56
Drug Usage Report	56
<u>GP2GP</u>	56
GP2GP PATIENT RECORD IMPORT	56
GP2GP PATIENT RECORD EXPORT	56
Advanced Forms	57
Display and use of Medications and Medical Warnings	57
Third Party Integrations	57
ManageMyHealth & SEHR	58
Patient Medications Data Upload	58
PATIENT MEDICAL WARNING DATA UPLOAD	58
PHO Clinical Event Export	59
Clinical Performance Indicators - Statins	59
New Zealand ePrescribing Service	59
Phorman SA	
FHUIHIUC SA	59
Prescribing Assistant	59

What is BPACNZRx?

Medtech32 now offers the NZF drug formulary as an alternative to the MIMS integrated formulary for prescribing and medical warnings. A practice can enable the NZF drug formulary as an alternative to the MIMS integrated formulary based on their choice as a practice. The NZF drug formulary aims to create the safest user friendly prescribing platform, and provides continued use of all existing prescribing functionality, where possible, along with additional features and functionality available based on the NZF drug data.

Medtech and BPAC NZ have enabled New Zealand Formulary integration into the Medtech32 platform. These integration and medical warning enhancements have been branded as BPACNZRx.

The MIMS and NZF integrated formularies mostly function in a similar fashion. The details below indicate significant differences when using BPACNZRx which includes aspects for consideration in regards to Patient Prescribing continuity:

- Drug-to-Drug Interaction checks utilise Stockley's Interaction Alerts engine, an internationally recognised accurate source of drug interactions.
- Medication terms may be longer, as these will be sourced from the NZ Universal List of Medicines.
- The ability to filter medication Unsafe in Pregnancy has been removed and has been replaced by always displaying a portion of the Pregnancy section of the associated medication monograph during prescribing.
- The Banned in Sports filter control to manage medications for athletes has been enhanced.
- Access to Medication Monograph information (i.e. NZ Formulary link) requires an internet connection.
- Section 29 medications are highlighted during the prescribing process and printed on a prescription.
- It was recognised that "Alert Fatigue" amongst prescribing clinicians is very real. This affects clinicians by conditioning them to ignore the many and frequent warnings which at times can feel unhelpful. BPACNZRx allows less important drug-to-drug interactions, such as 'Information only' to be suppressed (at individual prescriber level).
- BPACNZRx has also added a new mandatory medication alert field called "Severity". When prescribing a medicine classified with severe allergy, a Clinician will receive a warning prompt and be prevented from prescribing the medication.
- Whilst all medication warnings must be re-classified, clinicians also have the option of viewing and editing warnings during the prescribing process, as well as choosing to display or suppress warnings for allergies classed as mild.
- Patient drug allergies checks now include Excipient substances within the medication.
- BPACNZRx is committed to continually enhancing its capacity and speed. Monthly updates can be downloaded directly from within Medtech32.

Restrictions of the BPACNZRx solution

There are a number of restrictions that should be understood with regards to the use of the BPACNZRx integrated New Zealand Formulary data within Medtech32:

Pregnancy warnings are displayed regardless of age

Pregnancy monograph information displays for all patients regardless of their age or gender (This is important as some medications may affect male fertility) in this release of BPACNZRx. BPACNZRx may introduce user controlled settings in future releases to allow a provider to set the age boundaries for presenting the pregnancy warnings.

No ability to suppress drugs 'at risk when pregnant'

The approach of using pregnancy risk categories has several limitations, including that:

- It does not provide information about risks across different trimesters of pregnancy
- Medicines with a wide range of associated risks could be included in the same category
- The categories imply a grading system, which could lead to prescribing based on the risk category rather than an understanding of the evidence of risks and benefits for a particular patient
- The single-letter classification system does not provide enough information to support informed decision making by prescribers and patients

As a result of these shortcomings, there is an international movement away from using pregnancy safety categories, and in their place providing descriptions, where applicable, of the underlying evidence, degree of severity, timing of effects on the developing foetus and areas where there is a lack of evidence.

BPACNZRx includes brief advice on the safety of medicines in pregnancy and lactation from the textbook 'Drugs in Pregnancy and Lactation 2017' (used by permission from Wolters Kluwer Health). This information is available in an expandable section in a medicine monograph.

Extention of Medical Warnings to allow 'Other Substance' allergies to be recorded

Substances which are contained within medications can be located within the Generic Name category such as peanuts/arachis oil, egg, soy oil & almond oil etc.

However, non-medicinal substance allergies can also be recorded within Other Substances such as Cow's milk, Fish & pollen etc.

Recording of these allergies may reveal relationships between medication & other substance allergies.

No cross-sensitivity checks

Alerting groups do not provide cross-reactivity drug checks in this release of BPACNZRx. BPACNZRx is reviewing the group structure and may add these checks in future releases.

Price may be incorrectly displayed

If prescribers identify any incorrect pricing information they are encouraged to report this to the NZ Formulary via their feedback page <u>https://nzf.org.nz/Feedback</u> However prices for non-subsidised products should not relied on due to the difficulty in maintaining up to date pricing.

Activation of BPACNZRx is at Database Level not Practice Level

If your practice shares a database with other practices, all practices will be activated when switching to BPACNZRx.

Registration for activation of BPACNZRx

All practices looking to adopt the BPACNZRx New Zealand Formulary Integration as an alternative to the MIMS drug formulary are required to register for the service before activation within Medtech32.

Practices are requested to contact BPAC directly on 0800 633 236 or email contact@bpacnzrx.org to complete the registration process.

The practice's **HPI Organisation Id will be required** as part of the registration process along with details of the number of prescribing PMS users and enrolled patients, and administrator contact details.

Once registration has been completed with BPAC, practices can complete the activation process of BPACNZRx within the Medtech32 application.

Important Note – De-activation of MIMS

It is the responsibility of a practice when activating BPACNZRx within Medtech32 to advise MIMS that the practice will no longer be a MIMS Subscriber. From this point the Practice will not be advised of any future MIMS monthly drug updates.

BPAC will notify customers when the monthly drug update is available.

Activation of BPACNZRx

Activating the BPACNZRx NZF integration for the first time

Help ► About Drug Formulary

The **About MIMS** menu item from the Help menu drop-down has been changed to **About Drug Formulary**. Through the **About Drug Formulary** menu an organisation can choose either the BPACNZRx (NZF) or MIMS drug formulary for activation.



To activate BPACNZRx drug formulary:

- 1. Ensure you are logged into Medtech32 as a user with System Admin access rights
- 2. Select Help > About Drug Formulary
- 3. Select the BPACNZRx option under the 'Drug Formulary Selection' section
- 4. View the 'New Zealand Formulary Website T & C's' by selecting the provided link
- 5. Click on the 'Register' button

About Drug Formulary	×
Drug Formulary Selection 🕜	
C MIMS Integrated	
BPACNZRx	
BPACNZRx Drug ALERT Information Medsafe	
New Zealand Formulary Website T & C's	<u>R</u> egister
MIMS Removal Information	
Issue Date: Version:	<u>0</u> K

6. A registration validity check will be performed and if the registration is found to be valid, the following prompt will display.



EMPOWERING HEALTH

About Drug Formulary	×
Drug Formulary Selection 🕜 C MIMS Integrated G BPACNZRx	
BPACNZRx Drug ALERT Information Medsafe	
New Zealand Formulary Website T & C's	<u>R</u> egister
MIMS Removal Information X Successfully registered for BPACNZRx OK	
Issue Date: Version:	<u>D</u> K

7. The Register button will update to 'Run BPACNZRx Drug Update'.

About Drug Formulary	×
Drug Formulary Selection @ C MIMS Integrated G BPACNZFX BPACNZFX Drug ALERT Information Medsale New Zealand Formulary Website T & C's	Run BPACNZRx Drug <u>U</u> pdate
MIMS Removal Information	
Issue Date: 01-Dec-2019 Version: 90(2019-11-27)	QK

- 8. Click on the 'Run BPACNZRx Drug Update' button to start the file download process.
- 9. Once the download has completed, BPACNZRx Activation prompt will be displayed with details of the pre-requisites necessary before the activation of BPACNZRx

Co	nfirmation	×
	To Activate BPACNZRx Formulary and disable MIMS	
	The following pre-requisites are required:	
 Acceptance of BPACNZRx Terms & Conditions 		
Read & Understood BPACNZRx Activation User Guide		
✓ All necessary historical medication related reports have been run		
 A Medtech database Backup & Restore has been performed 		
~	All other users must be logged out of Medtech	
	Do you wish to continue?	
	Yes No	



Important Note – Activation Process Information

Activation of BPACNZRx should be treated as a system upgrade and therefore all other users must be logged out of Medtech32 at the time of activation. The activation process may take some time to complete and is dependent on the size of the database, and as such it is recommended that activation of BPACNZRx be completed at a time where the practice is not required to be operational for a period of time.

Please ensure all pre-requisite requirements are completed before completing the activation of the BPACNZRx functionality.

It is recommended that you perform an Interbase Back Up and Restore process prior to your practice activating BPACNZRx if one has not been completed recently. The following prompt will be displayed during the Activation process as a reminder.

i	The Medtech Database has been Restored on 5/04/2018 12:24:24 PM However, Medtech suggests to perform Backup and Restore before BPACNZRx Activation
	ОК

10. After ensuring all of the pre-requisites are completed, click on the Yes option to continue with the BPACNZRx activation. The BPACNZRx Activation Process will be performed and the NZF Drug Update installed.

Drug Formulary Se	lection 🕜		
C MIMS Integrated			
BPACNZRx			
BPACNZRx Drug A	BPACNZRx Drug Update	×	
New Zealand For	• • • • • • • • • • • • • • • • • • •		
	Performing drug update. Please wait		ad Monthly File
	Processing database "Training Database 1"		
MIMS Removal Info			
	Duraine table MIMCIA		
	Fulging table Ministra		
	<u>–</u>		
	87		
		K Abort	Ī
			1
			4
l			
l		/	
l		/	
Issue Date: Version:			<u></u>
Issue Date: Version:			<u></u> K
Issue Date: Version:			<u>K</u>
Issue Date: Version	200/h178: Dure Ladete		
Issue Date: Version:	BPACNZRx Drug Update		х <u>Б</u> к
Issue Date: Version:	BPACNZRx Drug Update 2erforming drug update. Please wait		X
Issue Date: Version:	BPACNZRx Drug Update Performing drug update. Please wait		×
Issue Date: Version	BPACNZRx Drug Update Performing drug update. Please wait rocessing database "Training Database 1"		×
Issue Date: Version	BPACNZRx Drug Update Performing drug update. Please wait rocessing database "Training Database 1"		×
Issue Date: Version:	BPACNZRx Drug Update Performing drug update. Please wait trocessing database "Training Database 1"		× 0K
Issue Date: Version:	BPACNZRx Drug Update Performing drug update. Please wait rocessing database "Training Database 1"	•	×
Issue Date: Version:	BPACNZRx Drug Update Performing drug update. Please wait rocessing database "Training Database 1"		х <u>р</u> к
Issue Date: Version:	BPACNZRx Drug Update Performing drug update. Please wait trocessing database "Training Database 1"	•	×
Issue Date: Version:	BPACNZRx Drug Update Performing drug update. Please wait trocessing database "Training Database 1"	•••	<u></u>
Issue Date: Version:	BPACNZRx Drug Update Performing drug update. Please wait trocessing database "Training Database 1"	•	×



11. Once the NZF Drug Update and BPACNZRx Activation Process has been completed click on OK to the information prompt displayed.



12. The following MIMS Removal Information prompt will be displayed

More Inform	ation	×
MIMS Remov	al Information	
Information		
The integrated	BPACNZRx Formulary has now been successfully activate which includes all Practices that share this Medtech data You must re-login to observe the changes.	d for your organisation base.
	In addition the MIMS database is no longer accessibl however historical patient medications still remain.	e,
should M	This information prompt will be saved on the Desktop MIMS require evidence of this action in relation to their Term	o s & Conditions.
		Annen

These details will be automatically saved into the Medtech32 database and remain accessible from the Help > About Drug Formulary window by clicking on the 'MIMS Removal Information' button should MIMS require evidence of this action in relation to their Terms & Conditions.

About Drug Formulary	×
Drug Formulary Selection ? MIMS Integrated BPACNZRx BPACNZRx Drug ALERT Information Medsafe	
New Zealand Formulary Website T & C's	Run BPACNZRx Drug <u>U</u> pdate

13. Click on OK to close the Information prompt

After BPACNZRx activation the MIMS drug database will no longer be accessible, however, historical patient medications and medical warnings will still be displayed.

To view all of the changes to the Medtech32 application and the prescribing and medical warning changes on the patient record you must log out and back into Medtech32.

Important Note – BPACNZRx Registration

If during the BPACNZRx activation it is identified that your practice does not have a valid registration you will be prompted with a messaging advising that your 'Organisation's BPACNZRx registration is no longer current'

If this occurs, please contact BPAC NZ on 0800 633 236 or email <u>contact@bpac.org.nz</u> to renew or establish your registration for BPACNZRx

Important Note – NZF Monthly Update Download			
If the download of the NZF Monthly Update fails due to user access to the download location			
	the following message will be displayed:		
Error	×]	
	Sorry you do not have access to https://nzmtmsformularyaei3b-api.azurewebsites.net Please arrange access to this path via your IT Support <u>try</u> again.		
Please contact your the specified location	Please contact your practice IT Support for assistance in ensuring that you have access to the specified location and try the NZF Monthly Update download process again once access		

Switching from BPACNZRx back to MIMS

If the situation arises where your practice would like to change from the BPACNZRx integrated formulary back to the MIMS drug formulary you are advised to contact the Medtech Support Team to discuss the process for the activation of MIMS.

has been provided.

It is recommended that before contacting Medtech Support you complete the following:

- 1. Contact MIMS to re-establish the practice's MIMS Subscription, and obtain Registration details
- 2. Download and have available the latest MIMS drug formulary (Full Installation) from the MIMS website for Medtech32

Monthly Drug Updates

Help ► About Drug Formulary OR Tools ► Clinical ► Drug Update

The NZF Monthly Download availability will be advised to registered practices by BPAC directly as soon as the monthly update is available.

The NZF monthly drug updates can be downloaded and performed directly from the About > Drug Formulary window within the Medtech32 application.

To download and install the NZF monthly drug update:

- 1. Ensure you are logged into Medtech32 as a user with System Admin access rights
- 2. Select Help > About Drug Formulary
- 3. Select the BPACNZRx tab
- 4. Click on the 'Run BPACNZRx Drug Update' button



- 5. The download of the most recent monthly drug formulary will commence
- 6. Once the NZF Monthly Drug Update has downloaded, the following prompt will be displayed:





If you would like to complete the Drug Update at this time:

7. Clicking on the 'Yes' option will continue to perform the Drug Update

BPACNZRx Drug Update	×
Performing drug update. Please wait	
Processing database "Training Database 1"	
	<u>D</u> K <u>A</u> bort
	//

8. Once the NZF Drug Update process has been completed click on OK to the information prompt displayed.

🕒 BPACNZRx Drug Update	×
Performing drug update. Please w ait	
Processing database "Training Database 1"	
MedTech-32 X	
Database updated, 300405 rows affected	
ОК	
<u>D</u> K	<u>A</u> bort

If you would like to complete the Drug Update at a later date:

- Clicking on the 'No' option will close the Drug Update screen and return you to the About > Drug Formulary window. Click on OK to close the screen.
- 10. When you are ready to complete the Drug Update, repeat the same process as described above. The Tools > Clinical > Drug Update feature has been removed when BPACNZRx is activated.

Important Note – NZF Monthly Update Download

If the download of the NZF Monthly Update fails due to the practice's BPACNZRx registration having expired you will be prompted with a message advising that your 'BPACNZRx user registration has expired, and your medications information may be out of date'.

If this occurs, please contact BPAC NZ on 0800 633 236 or email <u>contact@bpac.org.nz</u> to renew or establish your registration for BPACNZRx

In addition all users should be logged out of Medtech32 during the Drug Update process.

medtech®

Drug Setup

Setup ► Clinical ► Drug

To accommodate the introduction of the New Zealand Formulary drug data within Medtech32, the following changes have been made in the Drug Setup screen:

Drug Class and Therapeutic Options

The **Therapeutic Options** tab has been removed as there is no information in the BPACNZRX NZF drug data to support this function. The **Drug Class** tab has been renamed **Alerting Group** and acts in a similar fashion by grouping medications for patient Medical Warning purposes.

Previous MIMS New/View Drug screen

S View Drug					
APO-AMOXI 250mg Cap					
Main	Coding Generics	Drug Class	Therapeutic Options	More Information Au	dit
Drug Details					
Ge	meric Name: AMOX1	/CILLIN			

New BPACNZRx New/View Drug screen

View Drug	×
OSPAMOX amoxicillin 100 mg/mL oral liquid: powder for	
Main Coding Generics Alerting Group More Information Audit	
Drug Details	
Generic Name: AMOXICILLIN 100 MG/ML ORAL LIQUID: POWDER FOR	
Brand Name: OSPAMOX	

NZULM Coding

The NZULM (Universal List of Medications) are responsible for the allocation new product codes as new products are introduced by Pharmac. This code is utilised as part of the NZePS prescribing. They also provision the product prescribing term which is utilised within BPACNZRx.

Within the **Coding** tab provision has been made to display the NZULM product code.

Both the MPUU (Medicinal Product Unit of Use) and TPUU (Trade Product Unit of Use) NZULM codes are displayed for reference.



EMPOWERING HEALTH

9 View Drug					×
AMOXIL PAEDIATRIC DROPS	6 amoxicillin	100 r	ng/mL ore	al liquid: p	owder
Main Coding Generics More Info	ormation Audit	1			
Therapeutic Group :					
Amoxicillin		ΠE	referred		
NZULM :	1004004100	011010	0		
MPUU	TPUU		13		
L					
Pharmacodes :					
206512					
Unload Ref:					
Community of the local sector of the local sec					
Search Add			<u>o</u> k	Cancel	<u>H</u> elp

Where the selected product is available in the form of a 'Pack' then both the MPP (Medicinal Product Pack) and TPP (Trade Product Pack) NZULM codes are displayed for reference.

CHAMPIX STARTER PACK varenicline 500 microgram tablet [11] () vareni Main Coding Genetics More Information Audit Therapeutic Group: Varenicline Varenicline NCULM: [10124721000116109 [10124721000116108 TPP TPP	-					×	
Main Coding Genetics More Information Audit Therapeutic Group :	CHAMPIX STARTER PACK varenicline 500 microgram tablet [11] () varenic						
Therapeutic Group : Varenicine Image: State	Main Coding Genetics More Informati	ion Audit					
Varencine Preferred NZULM : [10124721000116109 [10124771000116108 MPP TPP	Theraneutic Group						
NZULM : 10124721000116109 MPP TPP Pharmacodes	Varenicine		Prei	erred			
NZULM : 10124721000116109 MPP TPP CPharmacodes	1	_					
NZULM : [10124721000116109 [10124771000116108 MPP TPP							
Initial/200016105 Initial/200016105 MPP TPP CPbarmscodes	NZULM :				_		
	MPP	10124//100 TPP	0116108				
Pharmacodes							
	Pharmacodes :						
2380455	2380455						
Unload Bef	Unload Bef						
Search Add OK Cancel Helo	Search Add			OK	Cancel	Help	

To learn more about the NZULM, please refer to: <u>http://info.nzulm.org.nz/</u>

IMMP and Sport Categories

Within the **More** tab the IMMP (Intensive Medicine Monitoring Programme) option has been removed as IMMP is not available to either the NZF or MIMS drug formularies.

View Drug		
APO-AMOXI 250mg Cap Main Coding Generics Drug	Class Therapeutic Options More Information Audit	
Drug Options Cral Contraceptive Hospital Dispensary Only Hecommended by Specialist Special Authority Controlled Drug Subject to Part Charge Single Page Original Pack	Sport Category: P 💌 Pregnancy Category: A 💌	

Previous MIMS New/View Drug screen



The Sports Category list has also been updated to display the World Anti-Doping Agency (WADA) Sports Categories, which allows more granular drug filtering when prescribing.

🕑 New Drug			×
Descr (CODE)			
Main Coding Generics More Drug Options Oral Contraceptive Hospital Dispensary Only Recommended by Specialist Special Authonity Controlled Drug Subject to Part Charge	Information Audit Sport Category: Pregnancy Category:	▼ S1 ∧ S2 S3 S4 S5 S6 S7 S6 S7	
Controlled Drug Subject to Part Charge Single Page Original Pack		54 55 56 57 58	

To learn more about the NZF Sport Categories, please refer to: <u>https://nzf.org.nz/nzf_239</u>

medtech®

Staff Setup

Setup ► Staff ► Members ► Provider Messages tab

To accommodate the introduction of the New Zealand Formulary drug data within Medtech32, the following changes have been made in the Staff Setup screen:

Enable Repeat Script without Old Drug Warnings

Within the Provider Messages tab, the **Enable Repeat Script without Old Drug Warnings** option has been removed. This is to ensure that users are not able to repeat prescriptions for old / unmapped MIMS medications by overriding the prompt to re-map to the equivalent NZF medication.

Options Print Enrolment forms with Encounter Slips □ Display Ethnicity Prompt Message Display Ethnicity Prompt Message ☑ Enable Granular Prescribing Directions Display Stat Warning Message ☑ Display Stat Warning Message Display Stat Warning Message ☑ Default Genetic Substitution Allowed Enable ability to Add @ Read Codes ☑ Auto Prompt System Diagnostics ☑ ☑ Prompt when filing an abnormal inbox report	Eligible to Code the Enable Repeat Scrip Display Interaction Varning M Osplay all Interact Display all Interact Display all Interact Display Drug to Dr Display Drug to All	Prescription pt without 0 Warning Me lessage tion Warning rug Interacti lergy Interact	n for Co-Payme Ild Drug Warni isssage gs on Warnings (otion Warnings)	int ings Dnly Only
		<u>0</u> K	<u>C</u> ancel	<u>H</u> elp

Previous MIMS New/View Staff screen

New BPACNZRx New/View Staff screen



Display warning for MILD patient Medical Warnings

Within the Provider Messages tab, a new **Display warning for MILD patient Medical Warnings** option has been added. This is to ensure that users are prompted with a Medical Warning alert message even when the medical warning being presented is of Mild Severity.

By default this option is selected for all providers and can be unselected if the provider does not want to receive MILD patient Medical Warning alert prompts.

Options		
Print Enrolment forms with Encounter Slips	Display warning for MILD patient Medical Warnings	
Display Ethnicity Prompt Message	Display Interaction Warning Message	
Enable Granular Prescribing Directions	Interaction Warning Message	_
Display Stat Warning Message	 Display all Interaction Warnings 	0
Default Generic Substitution Allowed	C Display Specific Interaction Warnings	
🔽 Enable ability to Add @ Read Codes	Display only Action based Interactions	Ţ
Auto Prompt System Diagnostics	Directory only Constitution and Internetions	-
🔽 Prompt when filing an abnormal inbox report	Display only sevency based interactions	
Eligible for Prescription Co-Payment	Display only Evidence based Interactions	~
	<u> </u>	lp

Interaction Warning Messages

The level of Drug Interactions that are displayed to a prescriber when prescribing using BPACNZRx can be configured at an individual level. By default the 'Display All Interaction Warnings' option will be applied to all prescribers.

Options Print Enrolment forms with Encounter Slips	Display warning for MILD patient Medical Warnings
Display Ethnicity Prompt Message Enable Granular Prescribing Directions Display Stat Warning Message Default Generic Substitution Allowed Enable ability to Add @ Read Codes	Display interaction Warning Message Interaction Warning Message Display all Interaction Warnings Display Specific Interaction Warnings Display Specific Interaction Warnings
Auto Prompt System Diagnostics Prompt when filing an abnormal inbox report Eligible for Prescription Co-Payment	Display only Action based Interactions T Display only Severity based Interactions T Display only Evidence based Interactions T
	<u> </u>

By selecting the 'Display specific Interaction Warnings' option the level of interactions to be displayed can be specified by selecting relevant sub-codes.

Options □ Print Enrolment forms with Encounter Slips □ Display Ethnicity Prompt Message ☑ Enable Granular Prescribing Directions ☑ Display Stat Warning Message ☑ Default Generic Substitution Allowed ☑ Enable ability to Add @ Read Codes □ Auto Prompt System Diagnostics ☑ Prompt when filing an abnormal inbox report ☑ Eligible for Prescription Co-Payment	✓ Display warning for MILD patient Medical Warnings ✓ Display Interaction Warning Message Thetraction Warning Message C Display all Interaction Warnings ☞ Display Specific Interaction Warnings ☞ Display only Action based Interactions ▲II (*) ☞ Display only Severity based Interactions ▲II (*) ☞ Display only Evidence based Interactions ▲II (*)	
	<u>QK</u> <u>C</u> ancel <u>H</u> e	۹b

Action based Interactions



- **Avoid**: For interactions where a drug combination is best avoided. This will mainly be used to highlight contraindicated drug pairs.
- Adjust: For interactions where the interaction can be accommodated, but where it is recommended that either one of the drugs is changed, or the dose is altered on initiating the combination.
- **Monitor**: For interactions where the drug pair is valuable and no compensatory action is possible, but the patient needs to be monitored to assess the outcome. For interactions where biochemical or therapeutic drug monitoring is recommended and further action may be needed based on the results.
- **Information**: For interactions where close follow up or monitoring are probably not automatically warranted due to the low probability of an interaction, but where more information is given in the event of a problem.



• No action: For interactions where no action is needed, or for drugs pairs where no interaction occurs.

Important Note – Action Based Interactions

For clinical safety reasons Avoid and Adjust action codes cannot be suppressed.

Severity based Interactions



- **Severe**: For interactions that could totally incapacitate a patient or result in either a permanent detrimental effect or a life-threatening event.
- **Unknown**: To be used only as a last resort. Designed for those interactions (such as the antiretrovirals), which are predicted but where there is insufficient evidence to even hazard a guess at the outcome.
- **Moderate**: For interactions that could result in an effect that may either cause considerable distress or partially incapacitate a patient. These interactions are unlikely to be life-threatening or result in long-term effects.
- **Mild**: For interactions that could result in an effect that is mild and unlikely to unduly concern or incapacitate the majority of patients
- **Nothing expected**: For interactions that are unlikely to result in an effect, or for drugs pairs where no interaction occurs.

Important Note – Severity Based Interactions

For clinical safety reasons Severe and Unknown severity codes cannot be suppressed.

Evidence based Interactions

Inter D D	action Warning Message isplay all Interaction Warnings isplay Specific Interaction Warnings	2	
☑	Display only Action based Interactions	All (*) 🗖	-
$\overline{}$	Display only Severity based Interactions	All (*) 🗖	•
	Display only Evidence based Interactions	All (*) 🗖]
	✓ I heoretical JU ✓ Case (1) ✓ Study (2) ✓ Extensive (3) ✓ All (*)		
	<u>0</u> K	<u>C</u> ancel	

- **Extensive**: For interactions where the information given is based on numerous small or medium size studies or several large studies. The information is usually supported by case reports.
- **Study**: For interactions where the information given is based on formal study. This may be one small or medium size study, or several small studies. The studies may or may not be supported by case reports.
- **Case**: For interactions where the information given is based either on a single case report or a limited number of case reports. No trials appear to have been conducted.
- **Theoretical**: For interactions where the information given is based on a theoretical interaction or lack of interaction. This information may have been derived either from in vitro studies involving the drug in question or based on the way other members of the same group act.

Careful consideration should be given before supressing alerts for prescribers and should be relative to their experience.

Should a prescriber wish to view any interactions which have been supressed the easiest method would be to utilise the Interactions feature available on the NZF website, <u>www.nzf.org.nz</u>.

Medical Warnings

Mapping MIMS Medical Warnings to NZF Medical Warnings

Module ► Clinical ► Medical Warnings

Following activation of BPACNZRx, existing MIMS Medical Warnings for a patient will be mapped and converted to the equivalent NZF Medical Warnings. Where the existing MIMS Medical Warnings are unable to be mapped and converted, the patient Medical Warnings will be retained in the Medical Warning list, and will be displayed in bold italic font, unless the patient has No Known Allergies (NKA) recorded or they have Note Only Medical Warnings recorded.

🕑 Medical Warr	nings			×
Date of Onset	Medical Warning	Severity	Note	^
18 Apr 2019			Peanut	
18 Aug 2017	benzylpenicillin			
18 Aug 2017	acetic acid			
05 Jul 2017	Penems			
03 Nov 2016	Penicillamine			
		1	'	¥

Double clicking on a patient medical warning that is currently displayed in bold italics in the patient Medical Warning list will prompt the user with the following message:



Once this is understood, you can disable this message by selecting the 'Do not display this information again' option.

Simply select the Generic Medication name associated to the Medical Warning and the associated Allergy Group is determined automatically.	
Do not display this information again	

Clicking on OK will open the View Medical Warning screen for re-mapping to be completed. If there is only one un-validated medical warning then this is opened automatically for updating.

At this stage BPACNZRx does not have combined medications for selection within medical warnings such as co-trimoxzole. If a patient has a recorded allergy for this medication then a medical warning should be created for BOTH active substances, namely Sulfamethoxazole & Trimethoprim.

🐨 Vie	w Medical Warning		
Main	Audit		6
Da	ate of Onset: 18 Aug 2017 🗾 👻		
	Old Type: Generic Group		
OLD Ge	eneric Group Benzylpenicillin		
	Old Note:		-
⊙ <u>Me</u>	dication C Other Substance C O	ther Important Note	
• Me • Ger Generic	dication C Other Substance C O neric Name: C Alerting Group S Name: benzylpenicillin	ther Important Note	
 Me Generic S 	dication C Other Substance C O neric Name C Alerting Group c Name: benzylpenicillin beverity: C Mild C Moderate	ther Important Note	
	dication C Other Substance C O neric Name C Alerting Group S Name: [benzylpenicillin Severity: C Mild C Moderate Note: [ther Important Note	
Generic	dication C Other Substance C O neric Name C Alerting Group Name: benzylpenicillin Severity: C Mild C Moderate Note:	ther Important Note	
	dication C Other Substance C O neric Name: C Alerting Group Name: benzylpenicillin Severity: C Mild C Moderate Note: Provider: Sam Eaves (SFE)	ther Important Note	
ি Me ● Gen Generic S F I	dication C Other Substance C O neric Name C Alerting Group Name: benzylpenicillin Severity: C Mild C Moderate Note: Provider: Sam Eaves (SFE) nactive: C	ther Important Note	

This mapping of the existing MIMS based Medical Warnings to new NZF based Medical Warnings is a pre-requisite for BPACNZRx prescribing to ensure patient Medical Warnings are displayed appropriately during prescribing of related medications.

Steps to remap a Medical Warning

On selecting and opening an existing MIMS based Medical Warning for a patient that requires mapping to an NZF based Medical Warning check and complete the following actions:

1. Confirm Date of Onset

The Medical Warning Date field has been renamed to Date of Onset. Therefore it is important that you check the accuracy of this date and change it if necessary to better reflect when the adverse reaction was first observed.

😢 View Medical Warning	×
Main Audit	0
Date of Onset: 18 Aug 2017	
Old Tupe: Generic Stoup	

2. Re-map the new Medical Warning Type

To assist in selecting the new Medical Warning Type for the patient Medical Warning the existing MIMS based Medical Warning information has been retained on the Medical Warning screen for all Medical Warnings that were unable to be mapped and converted to the equivalent NZF Medical Warnings during the activation of BPACNZRx.

🕑 View Medical Warning	×
Main Audit	0
Date of Onset: 18 Aug 2017	
Old Type: Generic Group	
OLD Generic Group Benzylpenicillin	
Old Note:	l in the second s
For details to convert old Medical Warning please open Hel	p icon 🕜

To remap the existing MIMS Medical Warnings select the Type of Medical Warning that is most appropriate for the patient Medical Warning.

Select from either Medication (e.g. Penicillin), Other Substance (e.g. Peanut or bee venom) or Other Important Note (e.g. Poor medication adherence) depending on the type of allergy that the patient has indicated or presented with.

View Medical Warning	×
Main Audit	0
Date of Onset: 18 Aug 2017 🗨	
Old Type: Generic Group	
OLD Generic Group Benzylpenicillin	
Old Note:	_
For details to convert old Medical Warning please open He	lp icon 🕜
Medication C Other Substance C Other Important Note	

If the Medical Warning type is selected as Medication:

If Medication is selected then select the sub-category of either Alerting Group or Generic Name.

🕙 View Medical Warning	×
Main Audit	0
Date of Onset: 18 Aug 2017 🗨	
Old Type: Generic Group	
OLD Generic Group Benzylpenicillin	
Old Note:	
For details to convert old Medical Warning please open He	lp icon 🕜
● Medication ○ Other Substance ○ Other Important Note	
Generic Name C Alerting Group	

Use the ellipsis button to search and find the appropriate Medication Alerting Group or Generic Name which is applicable. If known it is recommended to use Generic Name.

View Medical Warning ×	🕑 Find Generic Name —	- 🗆	×
Main Audit	Search: benzyl		
Date of Onset: 18 Aug 2017 🔹	🗖 Sha	ow All Gener	ic Names
Old Type: Generic Group	Generic S	Synonym	^
OLD Generic Group Benzylpenicillin	benzathine penicillin (as benzathine benzylpenicillin tetrahydrate)		_
Old Note:	benzylpenicilin		
For details to convert old Medical Warning please open Help icon 🕢	processe perzypersonn		
Medication C Other Substance C Other Important Note Security Name C Altring Surger			
Generic Name C Alerting Group			
Generic Name: benzylpenicillin			
Severity: O Mild O Moderate O Severe			
Note:			
Provider: Sam Eaves (SFE)			\$
<u>Q</u> K <u>C</u> ancel	<u> </u>		Cancel



EMPOWERING HEALTH

🕑 View Medical Warning	×	😢 View Alerting Group	-		×
Main Audit	0	Search: Den			
Date of Onset: 03 Nov 2016					
Old Type: Alerting Group		Alerting Group			<u>^</u>
OLD Drug Class Penicillamine		penicillamine and mercaptamine			
Old Note:					
For details to convert old Medical Warning please open Help i	icon 🕜				
Medication C Other Substance Other Important Note					
C Generic Name					
Alerting Group: pen					
Severity: C Mild C Moderate C Severe					
Note:					
Provider: Sam Eaves (SFE)					
Inactive:		<			~ ×
	Coursel 1		OF	1.0	- -
<u> </u>	Lancel		UK		ancel

If the Medical Warning type Other Substance is selected:

If the existing MIMS Medical Warning was related to Food, Animals or other Environmental substances it should be mapped within the Other Substance Medical Warning type.

View Medical Warning	×
Main Audit	0
Date of Onset: 03 Nov 2016 🗨	
Old Type: Drug Class	
OLD Drug Class Penicillamine]
Old Note:	
For details to convert old Medical Warning please open He	lp icon 🕜
C Medication © Other Substance C Other Important Note	

Use the ellipsis button to search and find the appropriate Substance which is applicable.

🕑 View Medical Warning 🛛 🕹	Find Substance	- 🗆 ×
Main Audit 0 Date of Onset: 03 Nov 2016	Search:	
Old Type: Drug Class	Substance	Synonym 🔨
OLD Drug Class Regional agring	Bee venom	
	Cow's milk	
Old Note:	Crayfish	lobster
For details to convert old Medical Warning please open Help icon 🔮	Eggs (edible)	
	Fish	
C Medication G Other Substance C Other Important Note	Gluten	
Stream and the substance of other important note	Peanut	peanuts
Susbtance: ····	Pollen	
Severity 🛈 Mild O Moderate O Severe	Sheirish	
	Soy Tree and	
Note:	Lifeent	
Rx Warning: 🔽	Abalone viscera poison	Dalla
Provider: Sam Eaves (SFE) 🗸		paaa
Inactive:	Abrasive agent	
	<	>
<u></u> Ancel		<u>O</u> K <u>C</u> ancel

Before creating an Other Substance medical warning a check should be made to ensure the substance does not exist within the Generic Name category, such as Peanut, Soy & Egg allergies.

In addition, should a patient have an intolerance to an intra uterine device (IUD) this can be located within the Other Substance list. But it is important to realise Other Substance allergies are NOT checked during the prescribing process, only Alerting Group & Generic Name medical warnings are checked.

medtech

If the Medical Warning type is selected as Other Important Note:

We recognise that many clinicians have used the Medical Warnings module to record miscellaneous information unrelated to Medications or Other Substances.

If the Other Important Note Medical Warning type is selected then enter the description in free text Note field provided.

😢 View Medical Warning	×
Main Audit	0
Date of Onset: 04 Nov 1998 🗨	
Old Type:	
Old Drug Class:	
Old Note: Vomiting	
For details to convert old Medical Warning please open He	lp icon 🕜
C Medication C Other Substance C Other Important No	te

The contents of the OLD Note field for the existing MIMS Medical Warning will automatically be displayed in the new NZF Medical Warning note field.

Old Drug Class: Old Note: Vomiting	
For details to convert old Medical Warning please op	en Help icon 🕜
C Medication C Other Substance 🕝 Other Importa	nt Note
Note: Vomiting	
Rx Warning: 🔽	
Provider: Sam Eaves (SFE)	
Inactive: 🕅	
<u></u>	K <u>C</u> ancel

Important Note – Other Important Notes field

We recognise that many clinicians have used the Medical Warnings module to record miscellaneous information unrelated to Medications or Other Substances. Medtech recommends that you Do NOT enter Medication related Medical Warnings on to the patient's medical record using the Other Important Note option as this will introduce clinical risk to the patient when prescribing. Ensure for Medication related Medical Warnings that the Medication option is selected.

3. Assign Severity

Recording Severity is a new and important categorisation for the patient's Medical Warning. Recording of a Severity is mandatory in all Medical Warnings.

Medication C Other Substance Generic Name C Alerting Group	C Other Important Note
Generic Name: benzylpenicillin	
Severity: O Mild 📀 Mode	rate O Severe
Note: Rash on arm	
Provider: Sam Eaves (SFE)	•
	<u> </u>

A clinical judgement is required in relation to the patient's reaction to the drug or substance. The severity of the allergy can be selected as either Mild, Moderate or Severe.

- Severe this should be selected if the Medical Warning is Life-Threatening or severe enough for the drug/substance not to be prescribed or the patient not be exposed to the substance.
- **Moderate** this should be selected if the Medical Warning is moderate or not severe enough and the drug/substance can be prescribed again if deemed necessary. It is an alert that indicates alternatives should be considered but may be ignored based on clinical judgement.
- **Mild** this should be selected if the Medical Warning is mild or tolerable for the patient, allowing the warning to be ignored if necessary in conjunction with clinical judgement. It is an alert that may either be ignored and/or indicates that alternatives should be considered.

Important Note – Medical Warning Severity

If you mark the allergy/warning as Severe (i.e. life-threatening reaction) then in the interest of patient safety the system will prevent accidental prescribing of medications associated with the selected Generic Name or Alerting Group.



4. Check Medical Warning Notes

The contents of the OLD Note field for the existing MIMS Medical Warning will automatically be displayed in the new NZF Medical Warning note field.

Old Drug Class:	
For details to convert old Medical \	∦arning please open Help icon 🕜
C Medication C Other Substance	© Other Important Note
Note: Vomiting	
Rx Warning: 🔽	
Provider: Sam Eaves (SFE)	-
Inactive:	
	<u>O</u> K <u>C</u> ancel

Important Note – Medical Warning Notes

Patients may have a number of Medication based Note Only Medical Warnings which presents a clinical risk when prescribing. Therefore it is recommended the prescriber takes opportunity to reclassify them as Medication based Medical Warnings, so they are only displayed where applicable during prescribing, rather than viewing them for every medication which occurs when Rx Warning is ticked.

5. Check the Rx Warning status

For Other Substance or Other Important Note Medical Warning types indicate if you DO NOT want it displayed when prescribing by unticking the Rx Warning option.

Rx Warning: 🔽		
Provider: Sam Eaves (SFE)	•	
Inactive:		
	<u>0</u> K	<u>C</u> ancel

Once the re-mapping of the Medical Warning appears valid, click on the OK to save the updated Medical Warning to the patient record.

medtech®

EMPOWERING HEALTH

🕑 View Medical Warning	×
Main Audit	0
Date of Onset: 18 Aug 2017 👻	
Old Type: Generic Group	
OLD Generic Group Benzylpenicillin	
Old Note:	
For details to convert old Medical Warning please open Help i	icon 🕜
Medication C Other Substance Generic Name C Aletting Group	
Generic Name: benzylpenicillin	
Severity: C Mild © Moderate C Severe	
Note: Hash on am	
Provider: Sam Eaves (SFE)	
Inactive:	
<u></u> K	<u>C</u> ancel

During the save process the following information message will be presented to the user advising them that a medical warning for the specific medication has been created, and will prompt alert messages at the time of prescribing, including for all associated medications contained within the same Alerting Group:



If the updated Medical Warning was marked with a Severity of Severe, the following information prompt will also be displayed:



The Medical Warning will no longer be displayed in bold italics within the Medical Warning list for the patient and provided there are no more patient Medical Warnings displayed in bold italics, prescribing will be permitted for the patient.

🕑 Medical Warnings 📃 🗉 💌					
Date of Onset	Medical Warning	Severity	Note	^	
04 Nov 1998	amoxicillin	Severe	Rash on arm		

Clicking on Cancel in the View Medical Warning screen at any point during the re-mapping process will discard your changes and return you to the Medical Warning list screen for the patient.

Important Note – Medical Warning list screen

The patient Medical Warning list screen will no longer be displayed in created Date Order. It will instead be displayed in Severity Order of Severe, Moderate and Mild.

🕙 Medical Warn	ings		- • •	<
Date of Onset	Medical Warning	Severity	Note	^
04 Nov 1998	amoxicillin	Severe	Rash on arm	
23 May 2019	penciclovir	Moderate		
23 May 2019	Animal feed	Mild	Sickness	

Important Note – Re-mapping prior to eReferral or GP2GP transfer The existing MIMS Medical Warnings for a patient DO NOT need to be re-mapped should a patient require an eReferral or a GP2GP record transfer to be completed before further prescribing within BPACNZRx.

Creating a New Medical Warning

Module ► Clinical ► Medical Warnings ► New

The accurate recording of a Patient Medical Warning is critical for the continued well-being of a patient, especially in the areas of allergies to Medications and Vaccines.

Recording a Medical Warning helps ensure the patient is not prescribed a medication or administered a vaccine that may have an adverse effect on the patient's health.

Important Note – Recording of Vaccine Allergies

There is currently no link with Vaccine allergies and the Immunisation module. The patient's Medical Warning list must be manually checked PRIOR to administering a Vaccine.

The Medical Warnings in BPACNZRx has been designed to allow creation of medical warnings more effectively and efficiently via the use of radio buttons and predictive searching.

New Medical Warning	×
Main Audit	0
Date of Onset: 22 Aug 2019	
,	
Medication Other Substance Other Important Note	
Generic Name C Alerting Group	
Generic Name:	
Severity: C Mild C Moderate C Severe	
Note:	
Provider: Sam Eaves (SFE)	
Inactive: 🗔	
<u> </u>	<u>C</u> ancel

Date of Onset: the date the allergy event is identified should be recorded; this field defaults to the current day's date but can be changed when creating the Medical Warning.

Type: select the type of Medical Warning according to the type of allergy. The following types are available:

- **Medication**: to select the required generic drug name or the Alerting Group, type the first few letters of the Generic medication name or Alerting Group of the drug in the field then press the ellipsis button to display potential matches. The search criteria can be further refined if what you are looking for is not displayed. In doing so the displayed results are automatically updated. Highlight the required term from the listing and press the Enter key to select or the ok button. The selected term will be displayed in the Medication field of the Medical Warnings screen.
- Other Substance: to select the required substance, type the first few letters of the substance name of the drug in the Keywords field then press the Search or press the Enter key to display potential matches. Highlight the required substance name from the listing and press the Enter key to select. The selected substance name will be displayed in the Substance field of the Medical Warnings screen.



- Other Important Note: This should ONLY be used if the Medical Warning does not fit in to either of the above two categories. To include allergy related information within this category could introduce clinical risks for the patient and should be avoided. For example a patient could have an Other Important Note and a No Known Allergies recorded, hence if the Note contains allergy information then the patient records are in conflict and will introduce clinical risk for the patient.
- No Known Drug Allergies (NKA): this option will only be present in the Medical Warning module if the patient has no ACTIVE Medical Warnings, excluding Other Important Notes. On opening the New Medical Warning screen, it will automatically default to the No Known Allergies option.

😢 New Medical Warning		×
Main Audit		0
Date of Onset: 23 May 2019	•	
C Medication C Other Substance	O ther Important Note	

If the No Known Allergies option is selected for a patient, the 'Note' field will be automatically updated with the text (NKA).

If a patient Medication or Other Substance Medical Warning is subsequently added, the No Known Allergies warning is automatically removed from the patient Medical Warnings and does not require manual removal.

Medication and Other Substance Predictive Searches

A predictive searching feature has been introduced in both the Find Generic Name & Alerting Group (Medication Medical Warning types) and Find Substance (Other Substance Medical Warning type) screens which automatically displays matches based on what is entered in the search field. For example, if A is entered in the search field all names beginning with A will be displayed resulting in a reduced number of mouse clicks.

New Medical Warning	\times	Find Substance —		×
Main Audit Date of Onset: 23 May 2019	0	Search: a		
C No Known Allergies		Substance	Synonyi	n 🔨
C Medication		Abalone viscera poison	paua	
		Abatacept		
Susbtance: ····		Abrasive agent		
Severity: Mild C Moderate C Severe		Abrin		
		Abscisic acid		
Note:		Absinthe		
Rx Warning: 🔽		Acacia		
Provider: Sam Eaves (SFE)		Acamprosate		
la settina E		Acarus siro protein		
Inactive: J				. *
		<		>
<u>QK</u> <u>C</u> ar	ncel	<u>K</u>	<u>C</u> a	ncel



As more characters are entered into the screen, fewer results are automatically displayed.

New Medical Warning	\times	🕑 Find Substance —		×
Main Audit	0	Search: abs		
C No Known Allergies		Substance	Synonym	^
C Medication Other Substance Other Important Note		Abscisic acid Absinthe		_
Susbtance:				
Rx Warning: Provider: Sam Eaves (SFE)				
Inactive:		<		× *
<u> </u>	Cancel	<u><u> </u></u>	<u>C</u> anc	;el

When searching for Other Substances, the most common allergic substances are displayed at the top of the list in alphabetical order, therefore, if the patient has a common allergy, no search criteria is required.

Find Substance	-		
Search:			ļ
Substance	Synonym	/	5
Bee venom			
Cow's milk			
Fish			
Gluten			
Intrauterine contraceptive device	IUD		
Pollen			
Shellfish			
Soy	Soya bear	n	
Tree nut			
Wheat			
Substance not assigned code in SNOMED			
Abalone viscera poison	Paua		
Abrasive agent			
Abrin			
Abscisic acid			
Absinthe			,
<		>	
	<u>0</u> K	<u>C</u> ancel	1

Severity: three levels of Severity can be specified; this requires clinical judgment in relation to the patient's reaction to the drug or substance.

- Severe this should be selected if the Medical Warning is Life-Threatening or severe enough for the substance not to be prescribed (system checks are limited to Peanuts & Eggs based products) or the patient not be exposed to the substance.
- Moderate this should be selected if the Medical Warning is moderate or not severe enough and the substance can be prescribed again if necessary. It is an alert that indicates alternatives should be considered but may be ignored based on clinical judgement.
- **Mild** this should be selected if the Medical Warning is mild or tolerable for the patient, allowing the warning to be ignored if necessary in conjunction with clinical judgement.



It is an alert that may either be ignored and/or indicates that alternatives should be considered.

Severity of Medical Warnings is a new feature with radio buttons alongside the grading of Mild, Moderate and Severe, which can be applied to Medications.

There is no default value of Severity for a New Medical Warning and must be selected based on clinical judgement.

Medication O ther Substance O Other Important Note Generic Name							
Gen	eric Name: b	enzylpenicillin					
	Severity: 🤿	Mild O I	Moderate C	Severe			
	Note:						
	Provider: S	am Eaves (SFE)		·			
				<u>0</u> K	<u>C</u> ancel		

Once a severity value is selected (e.g. Mild), it will be emphasised in bold font and the other values are left inconspicuous.

Gen	eric Name:			
	Severity: 🕢 Mild	C Moderate	O Severe	
	Note:			

When Severe is selected, it is emphasised in red bold font.

Gene	eric Name:		
	Severity: C Mild	C Moderate	Severe
	Note:		



As with medication allergies/intolerances, the Severity level can also be set for Other Substances. If the Other Substance Medical Warnings need to be displayed during prescribing then Rx Warning must be ticked.



However, if deemed clinically necessary, the severity value of the medical warning can be altered by double clicking the relevant medical warning in the prescribing interaction grid.

medtech®

EMPOWERING HEALTH

🕙 Ne	w Patient Medicati	on				\times
Main	Audit				G	MS: A4Z
H	Drug: Ortho-Dichlo	robenzene 14	% (140 Mg/Ml)	+ Para-Dichlo	robenzene 2%	; (20 M •••
D	osage: ml	F	rea:		Period:	
	😌 View Medical	Warning				×
<u>D</u> ire	Main Audit					0
R	Date of Onset	22 Aug 2019	•			
Adm	C Medication	Other Su	bstance C	Other Importa	nt Note	Ē
Initial						
Р	Susbtance: Pe	anut				
Date of	Severity: 🔿	Mild (O Moderate	🕥 Se	vere	
	Note:					
Classif	Rx Warning: 🔽					ution
	Provider: Sa	m Eaves (SFE)	-		
	Inactive: 🗖					ria
Sp						amond 1
Previou	s Drua: 1					
						_
Intera	ain Audit GMS: A4Z Drug: Ortho-Dichlorobenzene 14% (140 Mg/Ml) + Para-Dichlorobenzene 2% (20 M Dosane:					
Main Audit GMS: A4Z Image: Drug: Ortho-Dichlorobenzene 14% (140 Mg/Ml) + Para-Dichlorobenzene 2% (20 M) Desane: main Free: Period: Image: Main Audit Image: Period: Image: Main Audit Image: Image: Period: Image: Main Audit Image: Image: Period: Image: Image: Main Audit Image: Image:						
	~					
	Add to Decement	OK	Another	Cancel	NZE	Halp
- F	add to P <u>e</u> rsonal		Another		NZF	Teh

Note: should it be necessary to add additional information in relation to the Medical Warning that is not covered in the other fields, it can be entered here.

Rx Warning: this field only appears when a Type of Other Substance or Other Important Notes is selected and is ticked by default. If this field remains ticked then the Other Substance or Other Important Note Medical Warning will be displayed within the Rx Interactions section when prescribing any medication.

Provider: specify the staff member who recorded the patient Medical Warning. This will default to the logged in Provider.

After entering the required details, clicking OK will apply validation rules and save the Medical Warning to the patient record.

During the save process the following information message will be presented to the user if they have selected a Medical Warning type of 'Medication' advising them that a medical warning for the specific medication has been created, and will prompt alert messages at the time of prescribing:

Informat	ion X
i	You have marked a Medical Warning against medication ''amoxicillin''. This medication belongs to the Allergy group ''penicillin antibiotic''.
	Any drug from this group(s) is prescribed a warning message will be displayed for your consideration.



If the new Medical Warning was marked with a severity level of Severe, the following information prompt will also be displayed:



Patient Medications

Mapping MIMS Medications to NZF Medications

Module ► Clinical ► Patient Medications

Following activation of BPACNZRx, existing MIMS Medication records for a patient will be mapped and converted to the equivalent NZF Medication records. Where the existing MIMS Medication records are unable to be mapped and converted, the patient Medications will be retained in the Patient Medication list. They will, however, be displayed in italic font and will be unable to be automatically repeated for the patient.

🕑 P	Patient Medica	tions				×
Rep	Date	Drug Name		Qty	Directions	^
	26 Mar 2018	Amoxycillin 250mg Cap		12	1 caps, Three Times Daily	Ī
	26 Mar 2018	Amoxycillin 250mg Cap		12	1 caps, Three Times Daily	
	26 Mar 2018	Atorvastatin 10mg Tab		12	1 tabs, Three Times Daily	
	26 Jan 2018	Simvastatin 10mg Tab		12	1 tabs, Three Times Daily	
	5 Dec 2018	Rivaroxaban 10mg Tab [15]		12	1 tabs, Three Times Daily	
	24 Aug 2018	Nidazolam Maleate 7.5mg Tab		0		
	24 Aug 2018	Lorazepam 4mg/1ml Inj (section 29)		0		
	24 Aug 2018	Diazepam 10mg/10ml Elixir (section 29)		12	1, Three Times Daily	
	15 Aug 2018	Warfarin Sodium 1 mg Tab		12	1 tabs, Three Times Daily	
	12 Feb 2018	Amoxycillin 250mg Cap		12	1 caps, Three Times Daily	
	18 Jan 2018	Penicillamine 125mg Tab		12	1 tabs, Three Times Daily	
	28 Nov 2017	Amoxycillin 250mg Cap		12	1 caps, Three Times Daily	
	28 Nov 2017	Paracetamol 120mg/5ml Oral Susp		15	15 mls, Immediately	
	15 Nov 2017	Panadol 125mg Supp		0	25 sup, Immediately	
	15 Nov 2017	Amoxycillin 250mg Cap		12	1 caps, Three Times Daily	¥

The mapping of the existing MIMS Medication records to new NZF based Medication records is a pre-requisite for BPACNZRx prescribing when repeating medications to ensure that during the repeating process a Medication for a patient is able to be successfully recorded and that all related Medical Warnings are displayed appropriately during prescribing of related medications.

Important Note - Repeating un-mapped (italic) Patient Medications

All existing MIMS based Medication records selected for repeating for a patient that are unmapped must be reclassified to the equivalent NZF Medication during the repeat prescribing process to avoid potential prescribing errors.

Please be aware that any patient Medications that are displayed in italics are not recognised by the Drug to Drug Interaction checks performed when prescribing.

Steps to remap a Medication record when selected for repeating

Selecting to repeat an existing MIMS based Medication (or multiple Medications) that requires mapping to an NZF based Medication (medication displayed in italics) will require you to check and complete the following actions:

1. Select patient Medications to Repeat

Select an existing MIMS based Medication (or multiple Medications) to repeat for a patient that requires mapping to an NZF based Medication. The existing MIMS based Medications that require mapping are those that are displayed in italics in the Patient Medication list.

(Patient Medications					
	B	1	🛛 🗹 🔛 🕅 📟 🚇 🧯			
	Rep	Date	Drug Name	Qty	Directions	^
		26 Mar 2018	Amoxycillin 250mg Cap	12	1 caps, Three Times Daily	
		26 Mar 2018	Amoxycillin 250mg Cap	12	1 caps, Three Times Daily	
		26 Mar 2018	Atorvastatin 10mg Tab	12	1 tabs, Three Times Daily	
		26 Jan 2018	Simvastatin 10mg Tab	12	1 tabs, Three Times Daily	
		5 Dec 2018	Rivaroxaban 10mg Tab [15]	12	1 tabs, Three Times Daily	
		24 Aug 2018	Midazolam Maleate 7.5mg Tab	0		
		24 Aug 2018	Lorazepam 4mg/1ml Inj (section 29)	0		
		24 Aug 2018	Diazepam 10mg/10ml Elixir (section 29)	12	1, Three Times Daily	
		15 Aug 2018	Warfarin Sodium 1 mg Tab	12	1 tabs, Three Times Daily	
		12 Feb 2018	Amoxycillin 250mg Cap	12	1 caps, Three Times Daily	
		18 Jan 2018	Penicillamine 125mg Tab	12	1 tabs, Three Times Daily	
		28 Nov 2017	Amoxycillin 250mg Cap	12	1 caps, Three Times Daily	
		28 Nov 2017	Paracetamol 120mg/5ml Oral Susp	15	15 mls, Immediately	
		15 Nov 2017	Panadol 125mg Supp	0	25 sup, Immediately	
		15 Nov 2017	Amoxycillin 250mg Cap	12	1 caps, Three Times Daily	~

2. Use the Drug Map screen to identify the closest NZF based Medication

On trying to repeat an existing MIMS based patient Medication (displayed in italics), the closest NZF based Medication matches will be listed for selection.

Please select a new medication from the list of alte	ernatives below or click	< 'Search' to select from	the full dru	g list.	
SA Drugs: 🗖 Subsidised: 🔽					
🕜 Exclude drugs in sports prohibited at All times 🥅	in Competition only 🕅	in selected sports	Rx Saf	ety [nfo	0
Brand/Generic	Form	Brand		Sub	7
Quetiapine 100 Mg Tablet (Dp-Quetiapine)	Tablet	DP-QUETIAPINE			Î.
Quetiapine 100 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE			Ì.
Quetiapine 100 Mg Tablet (Seroquel)	Tablet	SEROQUEL			Ì.
Quetiapine 100 Mg Tablet (Quetapel)	Tablet	QUETAPEL			i.
Quetiapine 200 Mg Tablet (Dp-Quetiapine)	Tablet	DP-QUETIAPINE			i.
Quetiapine 200 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE			į.
Quetiapine 200 Mg Tablet (Seroquel)	Tablet	SEROQUEL			Ì.
Quetiapine 200 Mg Tablet (Quetapel)	Tablet	QUETAPEL			Ĺ
Quetiapine 25 Mg Tablet (Dp-Quetiapine)	Tablet	DP-QUETIAPINE			l
Quetiapine 25 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE			ſ
Quetiapine 25 Mg Tablet (Seroquel)	Tablet	SEROQUEL			ŀ
Strength			Price	PML	Г
quetiapine 25 mg tablet			1.79		1
quetiapine 100 mg tablet			0.00		
quetiapine 200 mg tablet			0.00		
guetiapine 300 mg tablet			0.00		

Select the most suitable NZF based medication and strength (if it is not the one that has been selected automatically for you).



The checkbox 'Copy prescribing details from old medication' is ticked by default to preserve dosage, frequency, period, mitte and classification values in the existing MIMS based patient Medication record.

Drug Map
WARNING Quetiapine Fumarate This medication is from the old database and cannot be prescribed. Please select a new medication from the list of alternatives below or click 'Search' to select from the full drug list. [copy prescribing details from old medication]

(OR)

2. Use the Drug Search screen to identify the closest NZF based Medication

If there are no suitable NZF based Medication matches, then the **Drug Search** window can be launched by clicking the 'Search' button at the bottom of the Drug Map screen.

Strength		Price	PML	^
quetiapine 25 mg tablet		1.79		
quetiapine 25 mg tablet		0.00		
quetiapine 100 mg tablet		0.00		
quetiapine 200 mg tablet		0.00		
quetiapine 300 mg tablet		0.00		
				~
	<u>QK</u> Brand <u>NZF</u> Search	<u>C</u> ancel	Help	,

Select the most suitable NZF based medication and strength.

Drug Search				
Quick Advanced				
Drug Name: QUETIAPINE	<u>S</u> earch			
C <u>P</u> ersonal 📀 <u>B</u> rand/Generic			Include Ind	active: 🛙
SA Drugs: 🥅 Subsidised: 🥅				
Ø Exclude drugs prohibited in sports at all times ┌─ in selected sports ┌─	in Competition		Rx Sa	afety <u>I</u> nfo
Brand/Generic	Form	Brand		Sub
Quetiapine 25 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE		
Quetiapine 25 Mg Tablet (Dp-Quetiapine)	Tablet	DP-QUETIAPINE		
Quetiapine 100 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE		
Quetiapine 100 Mg Tablet (Dp-Quetiapine)	Tablet	DP-QUETIAPINE		
Quetiapine 150 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE		
Quetiapine 200 Mg Tablet (Dp-Quetiapine)	Tablet	DP-QUETIAPINE		
Quetiapine 200 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE		
Quetiapine 300 Mg Tablet (Dp-Quetiapine)	Tablet	DP-QUETIAPINE		
Quetiapine 300 Mg Tablet (Auro-Quetiapine)	Tablet	AURO-QUETIAPINE		
Quetiapine 25 Mg Tablet [6 Tablets] (&) Quetiapine 100 Mg Tablet [3 Tablet	Pack	SEROQUEL STARTER	R PACK	
Quetiapine 25 Mg Tablet (Seroquel)	Tablet	SEROQUEL		
Strength	Brand		Price	PML
quetiapine 25 mg tablet	Quetapel		1.79	9
quetianine 150 mg tablet	Auro-Quetia	pine	0.00)
questaplite 150 mg tablet		nine	0.00	
quetapine 200 mg tablet	Auro-Quetia	pine	0.00	-

The checkbox 'Copy prescribing details from old medication' is ticked by default on the Drug Map screen which was opened prior to the Drug Search screen to preserve dosage, frequency, period mitte and classification values in the existing MIMS based patient Medication record.



Important Note – Selection of Medication Strength

Care must be taken if you are selecting a Medication with a different strength. If this occurs default prescribing details/instructions for the Patient Medication will need to be altered appropriately.

3. Save the change in Medication name

Once the selection of the most suitable NZF based medication and strength has been completed click on the OK button to save the change from the MIMS based Medication to the selected NZF based Medication.

Strength		Brand	Price	PML	^
quetiapine 25 mg tablet		Quetapel	1.79		
quetiapine 150 mg tablet		Auro-Quetiapine	0.00		
quetiapine 200 mg tablet		Auro-Quetiapine	0.00		
quetiapine 300 mg tablet		Auro-Quetiapine	0.00		Υ.
☐ Add To Alternati <u>v</u> es List	<u> </u>	nd Add NZF	<u>C</u> ancel	<u>H</u> elp	

The New Patient Medication screen will be displayed, presenting the selected NZF based medication.

🕙 New Patie	ent Medication					×		
Main Audit]				GMS	5: A4		
🛐 Drug:	Quetiapine 25 M	g Tablet						
Dosage:	1 tablet	Freq:	Three Times	Daily (TDS) 🗖	Period: 5 d	lays		
<u>M</u> itte:	15 tablet				Amount:	49.67		
<u>D</u> irections:	1 tablet, Three T	imes Daily				~		
						~		
Repeats:	0				Optio	ons		
Administer :	oral		_	Administered in	i Clinic			
Initial Dispen:	sing Period:	days	V	^p rovider Eligibl	e for Co-Paym	ent		
Pro <u>v</u> ider:	Sam Eaves (SFE	E)	-	Prescribed E:	xternally			
Date of Issue:	27 May 2019	T	External Prov	ider:				
			7 Frequent	Dispense 🦳	🔽 Long Term	n		
Classification:			▼ Co	nfidential 🥅	Generic S	ubstitution		
Status:			•					
	Recommend	ed by Speciali	st 🔽	Patient meets	s Endorsement	Criteria		
Specialist:			Date Recom	mended:		<u></u>		
Previous Drug:	Quetiapine Fuma	arate				•		
Interactions	Course All	wan Doore	t "Cheek"					
3 Warnings	3 Warnings							
Suppress	Severe Int	eractions be	etween: Que	tiapine 25 M	lg Tablet; V	iagra Inf		
						Y		
Add to P	ersonal	<u>0</u> K	Another	<u>C</u> ancel	NZF	<u>H</u> elp		

medtech®

4. Check and complete the Medication directions

Check and complete the administration directions for the selected NZF based medication to ensure that they are correct. Where possible the dosage, frequency, period and mitte values in the existing MIMS based patient Medication record will be displayed by default.

•	New Pati	ent Mea	dication				×
М	ain Audit				G	MS: A4	
ſ	🖬 Drug:	Quetiap	ine 25 Mg ⁻	Fablet		•	••
	Dosage:	1	tablet	Freq:	Three Times Daily (TDS) 💌 Period:	4 days	
	<u>M</u> itte:	12	tablet		Amount:	39.74	
	Directions:	1 tablet	, Three Tim	es Daily		1	~
							× .

The 'Previous Drug' field will display the name of the previous MIMS based patient Medication that was selected before the change to the NZF based patient Medication.

opeoidilat							
Previous Drug:	Previous Drug: Quetiapine Fumarate						
Interactions	Severe Allergy: Peanut ""	-					
<u>Suppress</u>	ess test						
🛕 Details	Pregnancy: Pregnancy: Compatible/Maternal Benefit >> Embryo-Fetal Risk: P						
Add to Pe	rsonal <u>OK</u> Another <u>C</u> ancel <u>NZF</u> <u>H</u> elp						

5. Review Interaction Warning for the new Patient Medication

Once you have checked and completed the administration directions for the new Patient Medication review any Interaction Warnings that may be presented to you.

Interactions	Severe Allergy: Peanut ""	^
2 Warnings Suppress	Pregnancy: Pregnancy: Compatible/Maternal Benefit >> Embryo-Fetal Risk: F	
🛆 De <u>t</u> ails		~
Add to P <u>e</u> r	sonal <u>OK</u> <u>A</u> nother <u>C</u> ancel <u>NZF</u> <u>H</u> elp	,

6. Save the change in Medication record

Once you have reviewed any Interaction Warnings for the new Patient Medication that may be presented to you click on the OK button to save the new NZF based Medication.

Interactions	Severe Allergy: Peanut ""				
<u>Suppress</u>	Pregnancy: Pregnancy: Compatible/Maternal Benefit >> Embryo-Fetal Risk: P				
🛆 Details			~		
Add to Per	sonal	<u>0</u> K	Another Cancel NZF Help		

This will complete the repeating process for the Patient Medication, and make it available for any further re-prescribing in the Patient's Medication list.



EMPOWERING HEALTH



Important Note – Presentation on the Drug Map screen

The Drug Map screen will be presented for each of the patient Medications selected for repeating that are existing MIMS based Medication records that are yet to be reclassified to the equivalent NZF Medication. The process for mapping a patient Medication must be completed for each of the Medications one by one.

New Patient Medication

Module ► Clinical ► New Prescriptions

When the prescriber opens the prescribing screen for the first time after migrating to BPACNZRx, and the selected patient has unmapped Medical Warnings the following warning message will be displayed when selecting to create a New Prescription:



If the selected patient has multiple unmapped Medical Warnings in their patient record, on clicking OK, the Medical Warnings grid will be opened automatically.

🕑 Medical Warnings					
C 🖪 🖪					
Date of Onset	Medical Warning	Severity	Note	^	
18 Apr 2019			Peanut		
18 Aug 2017	benzylpenicillin				
18 Aug 2017	acetic acid				
05 Jul 2017	Penems				
03 Nov 2016	Penicillamine				
	1	1		¥	

If the selected patient has a single unmapped Medical Warning in their patient record, on clicking OK, the View Medical Warning will be opened automatically.

medtech®

EMPOWERING HEALTH

🕘 View Medical Warning	×
Main Audit	0
Date of Onset: 18 Aug 2017 🗨	
Old Type: Generic Group	
OLD Generic Group Benzylpenicillin	
Old Note:	-
For details to convert old Medical Warning please open He	lp icon 🕜
Medication Other Substance Other Important Note Generic Name: benzylpenicillin Severity: Mild Moderate O Severe	
Note:	
Provider: Sam Eaves (SFE) 🗨	
Inactive: 🗖	
<u>_</u> K	<u>C</u> ancel

On clicking Cancel, the prescribing process will be cancelled and the warning message will be closed.

Important Note – Medical Warning Mapping

All existing MIMS based Medical Warnings for a patient that are unmapped must be reclassified to the equivalent NZF Medical Warning and the Severity value set before prescribing for the patient is permitted to avoid potential prescribing errors.

To accommodate the introduction of the New Zealand Formulary drug data within Medtech32, the following changes have been made in the New Patient Medication screen:

NZF Drug Terms

The new NZF drug terms used for the BPACNZRx prescribing module may be longer than the previous MIMS drug terms as they include the component substances along with their respective strengths within a particular preparation.

🕙 New Patient Medication	×
Main Audit	GMS: A4
Drug: Amoxicillin 250 Mg/5	MI + Clavulanic Acid 62.5 Mg/5 MI Oral Liquid: Powder I
Dosage: mL	Freq: Period:
Pac <u>k(</u> s): mL (OP)	Amount:

Due to the long drug term, the full description of the drug may not be visible in the Drug field in the New Patient Medication screen when prescribing.

Should it be necessary to view the full NZF drug name, the field can be expanded by dragging the right side border of the New Patient Medications window. This feature also applies to **Directions** and **Interactions**.



EMPOWERING HEALTH

🛞 New Patie	nt Medication							×
Main Audit		GMS: A4						
Drug:	Egg Yolk Phospholipid 1.2 G/100 MI + Glyce	ol 2.5 G/100 MI + Soya Oil 10 G/100 N	41 + Triglycerides Medium Chain 1	0 G/100 MH	njection: Intrav	enous Infusio	η, 1 X 100 MI B	ottle ···
Dosage:	mg.g Freq:	Period						
Mitte:	mg.g	Amount						
Directions:								0
Repeats:	0	Options						~
Administer :	njection 💌 🗆 A	dministered in Clinic						
Initial Dispen	ing Period: 🛛 days 🔽 F	rovider Eligible for Co-Payment						
Provider:	Sam Eaves (SFE) 💌 🗖	Prescribed Externally						
Date of Issue:	25 May 2019 👻 External Provi	der						
Charlenstern	Prequent I)ispense 🔲 🔲 Long Term						
Classification:	✓ Cor	fidential 🔲 🔽 Generic Substitution						
Status:	•							
Specialist:	Recommended by Specialist Date Recomm	Patient meets Endorsement Unteria						
Previous Drug:		•						
Interactions	Severe Allergy: Peanut ""							,
1 Warnings Suppress								
🛆 Dejails								
Add to F	ersonal			<u>0</u> K	Another	Cancel	NZF	<u>H</u> elp

The size of the New Patient Medication Window will be remembered if 'Remember Screen Size' configuration is enabled for the user in Staff Setup.

BPACNZRx logo

The BPACNZRx logo will display in the Interaction Warning section at the bottom of the New Patient Medication screen when no Interaction Warning messages are displayed.



Clicking on the BPACNZRx logo will open the NZ Formulary website <u>http://www.nzformulary.org/</u> in the user default web browser.





Drug Search

When searching for a medication to prescribe to the patient, the Drug Search screen will now perform the drug search within the NZF drug database.

Drug Search	×
Quick Advanced	
Drug Name: AMOX Search	
C Personal 📀 Brand/Generic	Include Inactive:
SA Drugs: 🗖 Subsidised: 🥅	
② Exclude drugs prohibited in sports at all times	Rx Safety Info

The following itemises the changes to the Drug Search screen for the BPACNZRx prescribing module:

• Search by 'Therapeutic Options' has been removed from both the Quick and Advanced tabs

Drug Search	×
Quick Advanced	
Drug Name:	Search
Drug Search	×
Quick Advanced	
Iherapeutic Group:	• Search Preferred Medicines Only

• The 'Sub' filter has been renamed to its full term 'Subsidised'

Drug Search	×
Quick Advanced	
Drug Name:	ch
C Personal @ Brand/Generic	Include Inactive: 🗔
SA Drugs: 🗖 Subsidised: 🥅	

- Exclude 'Unsafe in Pregnancy' filter has been removed, as the pregnancy related information from the monograph will be displaying during prescribing which can be double clicked to open the monograph section to view the full contents.
- 'Exclude Banned in Sport' filter has been removed, and has been replaced with a new set of filter options which follow the World Anti-Doping Agency (WADA) classification of three categories:
 - Exclude drugs prohibited in sports at all times
 - Excluded in selected sports
 - Excluded in competition only



EMPOWERING HEALTH

C Personal C Brand/Generic	Include Inactive: 🗖
SA Drugs: 🗖 Subsidised: 🥅	
	Rx Safety Info

If a patient is a competitive athlete & subject to drug testing, then the '**Exclude drugs prohibited in sports at all times**' must be checked. If they are an athlete in an eye/hand coordinated sport, which bans beta blockers, then the '**in selected sports**' must be checked. Finally, if they are in competition or are about to compete, then '**in competition**' must ALSO be checked.

Clicking on the Help icon next to the new Sport filters will open and display Guidance on using these new filter controls.

More Information	×
BPACNZRx Sports Filter Help	
Familiarity of the BPACNZRx Sports Filter feature is necessary to athlete or sportsperson inadvertently being prescribed a banne important to realise the status of a medication can change and the <u>WADA website</u> is advised if there is uncertainty. Each applicable banned in sports medication is assigned a <u>single</u> is either S1-S9 or P1. Each filter control removes medications w following categories:	reduce the risk of an medication. It is also n additional check on Sports Category which ich belong to the
at all times: Categories S1-S5, inclusive In selected sports: Category P1 only In Competition: Categories S6-S9, inclusive	
By way of example If an athlete or sportsperson is subject to drug testing then at a selected/ticked.	Times <u>must</u> be

• A new 'Rx Safety Info' feature has been added to the Drug Search screen.

The Rx Safety Info feature is an important new feature which can be used to ensure a drug is not contra-indicated in hepatic and renal impairment, pregnancy and breast-feeding.

Clicking on the Rx Safety Info button on the Drug Search screen after selecting a medication will open the NZF Safety Information screen.

Drug Search		×	NZE Safety Information	×
Buick Adversed			We salety mornation	~
door [Advanced]				~
Drug Name: RITALIN	Search		View in the NZF for Children	
			Home > 4 Central nervous system > 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder	
C Eersonal C Brand/Generic		Include Inactive: 🗖	methylphenidate hydrochloride	
SA Drugs: Subsidised:				
Exclude drugs prohibited in sports at all times in selected sports in i	n Competition 🦳	Rx Safety Info	sately moonly (silow da)	
Brand/Genetic	Form Brand	Sub ^	Contra-indications	
Ritalin La - Methylohenidate Hydrochloride 60 Mg Capsule: Modified Release	Capsule RITALIN LA		severe depression; suicidal ideation; anorexia nervosa; psychosis;	
Ritalin La - Methylohenidate Hydrochloride 10 Mg Capsule: Modified Release	Capsule RITALIN LA		uncontrolled bipolar disorder, hyperthyroidism, cardiovascular disease	
Ritalin La - Methylohenidate Hydrochloride 20 Mg Capsule: Modified Release	Capsule BITALIN LA		(including neart failure, cardiomyopathy, severe hypertension,	
Ritalin La - Methylphenidate Hydrochloride 40 Mg Capsule: Modified Release	Capsule RITALIN LA		arrnythmias), structural cardiac abnormalities, phaeochromocytoma,	
Ritalin La - Methylphenidate Hydrochloride 30 Mg Capsule: Modified Release	Capsule RITALIN LA		vasculitis; cerebrovascular disorders; use of monoamine oxidase	
Ritalin - Methylphenidate Hydrochloride 10 Mg Tablet	Tablet BITALIN		inhibitor (MAOI) within 14 days; glaucoma	
Ritalin Sr - Methylphenidate Hydrochloride 20 Mg Tablet: Sustained Release	Tablet BITALIN SR			
		~	Cautions monitor for psychiatric disorders, anxiety or agitation; tics or a family history of Tourette syndrome; drug or alcohol dependence; epilepsy (discontinue if increased seizure frequency), susceptibility to angle- closure daucoma: avoid abruot withdrawid dvsphagia (<i>Concerta</i>)	
Strength		Price PML ^	tablet dose form not appropriate); restricted gastro-intestinal lumen	
methylphenidate hydrochloride 10 mg capsule: modified release		15.60	(Concerta® tablet dose form not appropriate)	
methylphenidate hydrochloride 20 mg capsule: modified release		20.40	Priapism Priapism has been associated with methylphenidate	
methylphenidate hydrochloride 30 mg capsule: modified release		25.52	treatment Priapism or any erection lasting longer than 4 hours	
methylphenidate hydrochloride 40 mg capsule: modified release		30.60 ¥	requires immediate medical attention to prevent long-term	`
Add To Alternatives List	ieneric Add NZF	Cancel Help	🛆 Datasheet	Close

As the 'Unsafe in Pregnancy' filter has been removed, it is important that a prescriber refers to the 'Rx Safety Info' section carefully before prescribing.



Important Note – NZF Safety Information

Unlike MIMS the NZF Safety Information is not stored locally in the practice's system. The NZF Safety Information is an online web-based resource, and requires an internet connection to be accessed. Being an online resource you can be assured that the information is as up to date as possible when using it, even if the latest drug update has not been run.

• Search by Therapeutic Group on the Advanced tab now provides a drill down to three levels of ATC (Anatomical Therapeutic Chemical) and is presented in a tree hierarchy

Find Therapeutic Group	×
Iherapeutic Group: Search	
⇒ Alimentary tract and metabolism	^
i∰ Anabolic agents for systemic use	
Antidiarrheals, intestinal antiinflammatory/antiinfective agents	
Antidiarrheal microorganisms	
Antipropulsives	
Electrolytes with carbohydrates	
Intestinal adsorbents	
Intestinal antiinfectives	
Intestinal antiinflammatory agents	
Other antidiarrheals	
Antiemetics and antinauseants	
Antiobesity preparations, excl. diet products	
Appetite stimulants	
Bile and liver therapy	
Bile therapy	
— Drugs for bile therapy and lipotropics in combination	
Liver therapy, lipotropics	
⊕ Digestives, incl. enzymes	
Drugs for functional gastrointestinal disorders	
吏 Drugs used in diabetes	
Laxatives	
Mineral supplements	
i 🗇 Other alimentary tract and metabolism products	
<u>O</u> K <u>C</u> ancel <u>H</u> elp	

- The first level of the code indicates the anatomical main group
- The second level of the code indicates the therapeutic main group
- The third level of the code indicates the therapeutic/pharmacological subgroup

Please Note: Some levels may not display any medications which means no drugs are currently available within NZ that belong to the selected category.

• The 'Generic Group' option on the Advanced tab has been renamed to 'Generic Name'

Drug Search	×
Quick Advanced	
Iherapeutic Group:	Search Defend Madicines Only E
G <u>e</u> neric Name:	
	-

• Searching for all the preparations for a particular drug name will show the list of preparations in order of Strength.



EMPOWERING HEALTH

					>
Quick Advanced					
Drug Name: PARACETAMOL 125	<u>S</u> earch				
C Bersonal C Brand/Generic			Include Ina	ctive:	_
SA Drugs: 🗖 Subsidised: 🥅					
Exclude drugs prohibited in sports at all times	in Competition		Rx Sa	fety <u>I</u> nl	io
Brand/Generic	Form	Brand		Sub	Г
Paracetamol 125 Mg Suppository (Panadol)	Suppository	PANADOL			í
Paracetamol 125 Mg Suppository (Paracetamol (Pharmacy Health))	Suppository	PARACETAMOL (PH/	ARMACY HEA.		l
Paracetamol (Pharmacy Health) - Paracetamol 125 Mg Suppository	Suppository	PARACETAMOL (PH/	ARMACY HEA.		
Paracetamol 125 Mg Suppository (Gacet)	Suppository	GACET			ſ
Strength	Brand		Price	PML	Г
Strength paracetamol 125 mo suppository	Brand		Price 3.29	PML	ŗ
Strength peracetamol 125 mg suppository peracetamol 125 mg suppository	Brand Gacet Paracetam	I (Pharmacy Health)	Price 3.29 0.00	PML	ŗ
Strength paracelamol 125 mg suppository paracelamol 125 mg suppository paracelamol 250 mg suppository	Brand Gacet Paracetam Paracetam	I (Pharmacy Health)	Price 3.29 0.00 0.00	PML	T
Strength paracetamol 125 mg suppository paracetamol 250 mg suppository paracetamil 050 mg suppository paracetamil 050 mg suppository	Brand Gacet Paracetam Paracetam Paracetam	I (Pharmacy Health) I (Pharmacy Health) I (Pharmacy Health)	Price 3.29 0.00 0.00 0.00	PML	J

In the interests of clinical safety and to assist in avoiding Prescribing errors, all medication 'sets' will be ordered by strength in ascending order, where the lowest strength is to be at the top and the highest at the bottom.

In addition, to support the predominantly prescribed subsidised medications, the subsidised medication will be selected by default within the strength grid which supresses other non-subsidised equivalents to be displayed.

Brand/Generic	Form	Brand	Sub	^
Amoxicillin 100 Mg/MI Oral Liquid: Powder For (Amoxil Paediatric Drops)	MI	AMOXIL PAEDIATRIC DROPS		Ī
Amoxil Paediatric Drops - Amoxicillin 100 Mg/MI Oral Liquid: Powder For	MI	AMOXIL PAEDIATRIC DROPS		Ī
Amoxicillin 125 Mg/5 MI + Clavulanic Acid 31.25 Mg/5 MI Oral Liquid: Powd	MI	ALPHA-AMOXYCLAV		ĺ.
Amoxicillin 125 Mg/5 MI Oral Liquid: Powder For (Moxlin)	MI	MOXLIN		Ì
Amoxicillin 125 Mg/5 MI Oral Liquid: Powder For (Miloxy 125)	MI	MILOXY 125		
Amoxicillin 125 Mg/5 MI Oral Liquid: Powder For (Amoxicillin Actavis)	MI	AMOXICILLIN ACTAVIS		
Amoxicillin Actavis - Amoxicillin 125 Mg/5 MI Oral Liquid: Powder For	М	AMOXICILLIN ACTAVIS		1
Amoxicillin 250 Mg Injection: Powder For (Amoxil)	Vial	AMOXIL		ĺ.
Amoxil - Amoxicillin 250 Mg Injection: Powder For	Vial	AMOXIL		Ì
Amoxicillin 250 Mg/5 MI + Clavulanic Acid 62.5 Mg/5 MI Oral Liquid: Powder	MI	ALPHA-AMOXYCLAV		Î
Amoxicillin 250 Mg/5 MI Oral Liquid: Powder For (Amoxicillin Actavis)	МІ	AMOXICILLIN ACTAVIS		v
Strength	Brand	Price	PML	^
amoxicillin 125 mg/5 mL oral liquid: powder for	Miloxy 12	5 0.	00	1
amoxicillin 125 mg/5 mL oral liquid: powder for	Alphamo	c 1.	20	1
				¥
	Brand	Add NZF Cancel	<u>H</u> elr	p

medtech[®] Section 29 Drugs

For Section 29 drugs, the term 'Section 29' is generally not included in the NZF drug term as it has been previously displayed for MIMS drug terms. Instead for Section 29 drugs you will now see the indicator displayed in bold blue font above the Drug field in the New Patient Medication screen.

Previous MIMS New/View Drug screen



New BPACNZRx New/View Drug screen

New Patient Medication		×
Main Audit	Section29	GMS: A4
🕅 Drug: Flutamide 250 Mg	Tablet	
Dosage: tablet	Freq:	Period:
Mitte: tablet		Amount:

Section 29 is also printed on the prescription for the attention of the Pharmacist Dispenser.

medtech®

Monographs

The full NZF monographs can be accessed through the NZF button at the bottom of the New Patient Medications and Drug Search Window.

	Interactions 2 Warnings Suppress Details	Severe Severe	Allergy: Pea Interactions	nut "" betwee	n: Flutar	nide 250	Mg Tablet; Q	luetiapii V	-	
	☐ Add to P <u>e</u> r	sonal	<u>0</u> K	And	ither	<u>C</u> ancel	NZF	<u>H</u> elp]	
										_
Strength								Price	PML /	ς.
acetylcystei	ne 600 mg tablet: disp	ersible						0.	00	
acetylcystei	ne 200 mg tablet: disp	ersible						0.	00	
										,
			Prescribe	<u>0</u> K	<u>G</u> eneric	<u>A</u> dd	NZF	Cancel	Help	

There are separate monographs available within the NZF for adults (blue header) and children (red header).

The type of monograph opened is predicated on the age of the selected patient recorded in the Patient Register. If the patient is aged 17 years or younger, the child monograph is opened.

So New Patient Medication	NZF Medicine Information	×
Main Audit GMS: Y4	Feedback Terms and Conditions, Disclaimer, and User Guide	
Drug: Aspirin 75 Mg Tablet: Enteric-Coated		
Dosage: tablet Freq. Period:		
Mitte: tablet Amount	NZ1 New Zealand Formulary for Children Open Menu	
Directions:		
	Search NZEC Interactions	
Repeats: 0 Options	Search NZPC Interactions	
Administer : oral 🛛 🗸 🦷 Administered in Clinic	Enter search term	
Initial Dispensing Period: days 🔽 Provider Eligible for Co-Payment		
Provider: Sam Eaves (SFE) Prescribed Externally		
Date of Issue: 25 May 2019 👻 External Provider: \cdots	View in the NZF	
🕜 Frequent Dispense 🗌 📄 Long Term		
Classification: Confidential Confidential	Home > 2 Cardiovascular system > 2.9 Antiplatelet drugs	
Status:	🛛 🛃 aspirin	
Recommended by Specialist Patient meets Endorsement Criteria	(acetylsalicylic acid)	
Specialist Date Recommended: 💌		
Previous Drug:	Drug action Aspirin is a salicylate non-steroidal anti-inflammatory drug	
Interactions 1 Warnings Suppress // A Degals	(NSAID) NSAIDs reduce prostaglandin production by inhibiting cyclo-oxygenase, resulting in analgesic, anti-inflammatory and anti-pyretic effects. Aspirin also reduces platelet aggregation and prevents thrombus formation by irreversibly inhibiting cyclo- oxygenase-1 in platelets, preventing their production of thromboxane A2.	~
Add to Personal <u>QK</u> Another <u>Cancel</u> <u>NZF</u> <u>Help</u>	Datasheet Clo	se

If the patient is older than 17 years of age, the adult monograph is launched.

New Patient Medication	NZF Medicine Information ×
Main Audit GMS: A4	Feedback Terms and Conditions, Disclaimer, and User Guide
Big Urug / Appril / S Mg ablet: Pries: Loaded Dosage: tablet Freq: Period. Mile: tablet Amount Drection:	New Zealand Formulary E Open Menu
Repeat: 0 Administer : [oral Administer : [orad Administer : [orad Administer : [orad Administer : [o	Search NZF Interactions Enter search term
Provider: [Sam Eaves (SFE) Provider: [Sam Eaves (SFE) Provider: [Provider: [Sam Eaves (SFE) Provider: [Sam Eaves (Statistical Contents Statistical Contents (Statistical Contents Statistical Contents Statistical Contents (Statistical Contents Statistical Cont	View in the NZF for Children Home > 2 Gardiovascular system > 2 9 Artiplateld drugs > Management of stroke
Status: Recommended by Specialist Patient meets Endocrement Diferia Specialist Date Recommended Y	riome > 4.Central nervous avstern > 4./ Analdesics > 4./ I. Non-sound analdesics aspirin (acetylsalicylic acid)
Previous Dag: Interaction: 2 Warning: Severe Allergy: Peanut *** Pregnancy: Pegnancy: Compable (Low Dose); Human Data Suggest Risk in A Detais V	Drug action Aspirin is a salicylate non-steroidal anti-inflammatory drug (NSAID). NSAIDs reduce prostaglandin production by inhibiting cyclo-oxygenase, resulting in analgesic, anti-inflammatory and anti-pretic effects. Aspirin also reduces platelet aggregation and prevents thrombus formation by irreversibly inhibiting cyclo-
Add to Pgrsonal <u>QK</u> Another <u>C</u> ancel <u>NZF</u> <u>H</u> elp	

You can switch between the adult and child monographs by selecting the blue or red banner at the top of the NZF Medicine Information screen.



Important Note – Monograph Terms and Conditions

On accessing the NZF Monographs for the first time the user will be presented with the 'Welcome to the New Zealand Medicine Formulary' page. Please review and accept the Terms and Conditions for use of the NZF formulary before proceeding by clicking on the Accept button.



This message will display once for NZF Adult Monographs and once for NZF Child Monographs.

Please Note: If the NZF button is selected from the New Patient Medication screen and the patient is 17 years or younger the monograph automatically positions at the Dosage section for quick access.

Interactions

The interactions grid will display Medical Warnings, pregnancy related information and the drug and Drug to Drug Interactions.

Interactions	Severe Allergy: Peanut ""
3 warnings Suppress	Pregnancy: Contraindicated 1 st Trimester: Pregnancy Summary:
🛆 Details	Severe Interactions between: Warfarin Sodium 5 Mg Tablet; As 🗸
Add to P <u>e</u> r	sonal <u>OK</u> <u>A</u> nother <u>C</u> ancel <mark>NZF</mark> <u>H</u> elp

The ordering of Interaction warnings displayed on the New Patient Medication screen will be:

- Patient Medical Warnings, related to the prescribed drug if any, ordered by Severity
- Other Substance Medical warnings with Rx Warning ticked, ordered by Severity
- Patient Note Only with Rx Warning ticked, ordered by date created, oldest at the top
- Pregnancy section from NZF monograph
- Drug to Drug interactions, ordered by Severity

Each of the strings of interaction information can be double clicked to get further details (e.g. pregnancy string and/or drug or drug to drug interaction information) or alternatively click the Details button when the relevant information is highlighted.

Interaction Information		×	NZF Medicine Information		
Interaction Summary: Action: Severity: Evidence: Disclaimer S Formulary dru Medtech Limit information th the NZ Formu	Is between: Warfarin Sodium 5 Mg Tablet; Viagra No pharmacokinetic interaction has been reported with sildenafil and warfarin, although increased bleeding (mostly nosebleeds) has been reported in patients taking sildenafil for pulmonary hypertension. Information – This interaction is not established, but bear these reports in mind in case of an unexpected increase in bleeding. Severe Case Vigence and the several several several several Vigence and the several several several several Vigence and the several several several several Vigence and the several several several several several Vigence and the several several several several several Vigence and the several severa	<	View in the NZF for Children High > 2.Cardiovascular system > 2.8 Anticovalurity and reversal agents > 2.0.2 Ord anticovalurity > Committee and plennidante Warfarin socility and a system and reversal agents > 2.0.2 Contra-indications Naemorrhagic stroke; significant bleeding or bleeding risk; avoid use within 48 hours postpartum Cattons See <u>Coundantis</u> ; also conditions in which risk of bleeding is increased, e.g. history of gastro-intestinal bleeding, peptic ulcer, recent surgery, recent ischaemic stroke, threatened abortion; hyperthyroidism or hypothyroidism (changes in thyroid hormone status or thyroid therapy can influence response to anticogalabloid, postpartum (delay warfarin until risk of haemonrhage is low—usually 5–7 days after delivers); uncontrolled hypoteriension, spinol or epidural anaesthesia, lumbar puncture; concomfant use of drugs that increase risk of bleeding, avoid cranberry luce; calciphylaxis		
Print To: 🚺	srosoft Print to PDF	.	Calciphylaxis Warfarin use has been associated with an increased risk of calciphylaxis—most often in patients with known	ose	

When these pop-out windows are displayed they can be sized & positioned to suit. If 'Remember Screen Size' configuration is enabled for the user in Staff Setup, then they are displayed as configured next time they are opened.

For a Medication or Other Important Note interaction warning, double clicking will open the relevant View Medical Warnings screen providing the ability to edit or change the medical warning such as changing the Severity of the Medical Warning from the Interaction display or marking it Inactive if it is no longer relevant to the patient or it is a duplicate.

medtech®

EMPOWERING HEALTH

ا 🕙	New Patient Medicat	ion				×				
Mair	Audit				(GMS: A4Z				
	Drug: Warfarin So	dium 5 Mg Tab	olet							
	Dosage: tab	let F	req:		▼ Perio	d:				
	<u>M</u> itte: tab	let			Amount	<u>.</u>				
D	🕙 View Medical \	Varning				×				
	Main Audit									
Ac	Date of Onset:	22 Aug 2019	•			·				
Init	C Medication 🕡	Other Sub:	stance C C	ither Importan	t Note					
Date	Susbtance: Pea	nut								
	Severity: 🔿 🕅	fild C	Moderate	Sev	ere					
Ulas	Note:					itution				
	Rx Warning: 🔽									
	Provider: Sam	Eaves (SFE)		-		:eria				
S	Inactive: 🗖									
Previo				<u>(</u>	<u>)</u> K <u>C</u> a	ancel				
Inte	ractions Severe	Allergy: Pea	anut ""			^				
3 Wa Sun	oress Pregnan	cy: Contraindic	ated∎1st Trime	ester: Pregnan	icy Summary:					
A Detaile Severe Interactions between: Warfarin Sodium 5 Mg Tablet; A: v										
			1		1	1 1				
	Add to Personal	<u>0</u> K	Another	<u>C</u> ancel	<u>H</u> elp					

Personal, Preferred and User-Defined Drugs

Personal Medicines

Setup ► Clinical ► Personal Medicines

Only Personal Medications which have been mapped automatically to NZ Formulary drugs will be available for prescribing after BPACNZRx activation.

Any Personal Medications that were created using MIMS drugs or historic Pharmac medications that could not be mapped to NZ Formulary drugs will no longer be available for prescribing after BPACNZRx activation and will need to be created as a new Personal Medications using the NZ Formulary drugs.

Preferred Medication

Setup ► Clinical ► Drug

As part of the BPACNZRx activation, the existing MIMS drug formulary is removed from the Medtech32 application. The selection of any MIMS drug as a 'Preferred Medication' will not be retained when the data is removed from Medtech32.

A provider must reinstate the Preferred Medication flags on the equivalent NZ Formulary drugs through the Setup > Clinical > Drug screen, and selecting the 'Preferred' option on the Coding tab for any drugs that they would like to be displayed as a Preferred medication.

🕙 New Drug		
Descr (CODE)		
Main Coding Generics More Info	rmation Audit	
• • •		
Therapeutic Group :		
	Preferred	
	··· Preferred	

User-Defined Drugs

Setup ► Clinical ► Drug

All currently configured User-Defined Drugs will be available for prescribing after BPACNZRx activation.

If a User-Defined Drug was mapped to a MIMS Generic Group (or Drug Class) previously in the Generics tab of the Setup > Clinical > Drug screen, it will need to be re-mapped to the equivalent NZF Generic Name (or NZF Alerting Group) after activation of BPACNZRx to ensure they can be suitably recognised when performing a patient Medical Warning cross check during prescribing. If no Generic Name or Alerting Group is specified no medical warning checks are possible.

medtech®

Reports

Drug Usage Report

Report ► Clinical ► Drug Usage Report

The Drug Usage Report will continue to function after activation of BPACNZRx.

Practices should, however, be aware that the Drug Usage Report will only report on drugs from the current drug formulary in use, being either MIMS or NZF.

It is recommended, if necessary, to run the Drug Usage Report prior to BPACNZRx activation to generate the report on any MIMS drug usage. Post activation, the report will only display NZF drug usage.

GP2GP

GP2GP Patient Record Import

Module ► Inbox ► Provider Inbox (or) Tools ► Patient ► GP2GP Patient Record Manual Import

The GP2GP Patient Record Import will continue to function after activation of BPACNZRx.

The GP2GP Patient Record Import has been enhanced to recognise NZULM (New Zealand Universal List of Medicines) codes. This will reduce the number of medications that are displayed in italics within the Patient Medication list after a GP2GP Patient Record import is completed, improving the ability to repeat the medication for the patient, provided the sending system passes NZULM codes.

GP2GP Patient Record Export

Tools ► Patient ► GP2GP Patient Record Export

The GP2GP Patient Record Export will continue to function after activation of BPACNZRx.

The GP2GP Patient Record Export has been enhanced to include NZULM (New Zealand Universal List of Medicines) codes. This will allow other Patient Management Systems to recognise Medications and Medical Warnings, regardless of the drug formulary in use.

Advanced Forms

Display and use of Medications and Medical Warnings

Module ► Advanced Forms

Medtech has been working with all known and approved Third Party Integrators that supply Advanced Forms utilising the Medtech database to practices. All third party Advanced Forms that are known to Medtech should continue to retrieve and display Patient Medication and Medical Warnings information after upgrade.

Medtech advises that you contact your Third Party Advanced Form providers to ensure that they have made any necessary changes to support the new Medtech database structure prior to upgrade prior to activation of BPACNZRx.

Medtech has provided a technical document that provides a summary of the changes, identifying both new and updated database tables for Third Parties that integrate into these areas of the Medtech32 application which can be downloaded from the Insight Customer Portal via the following link:

https://insight.medtechglobal.com/downloads/medtech32-resources/

Third Party Integrations

Medtech has been working with all known and approved Third Party Integrators that supply integrated modules utilising the Medtech database to practices. All third party integrations that are known to Medtech should continue to retrieve Patient Medication and Medical Warnings information after upgrade.

Medtech advises that you contact your Third Party integrators to ensure that they have made any necessary changes to support the new Medtech database structure prior to upgrade prior to activation of BPACNZRx.

Medtech has provided a technical document that provides a summary of the changes, identifying both new and updated database tables for Third Parties that integrate into these areas of the Medtech32 application which can be downloaded from the Insight Customer Portal via the following link:

https://insight.medtechglobal.com/downloads/medtech32-resources/

ManageMyHealth & SEHR

Patient Medications Data Upload

The patient Medications data upload to ManageMyHealth and the SEHR will continue to function after activation of BPACNZRx.

Request Repeat Prescription (RRP) messages coming from ManageMyHealth into Medtech32 will continue to function with BPACNZRx.

Patient Medical Warning Data Upload

The patient Medical Warning data upload to ManageMyHealth and the SEHR will continue to function after activation of BPACNZRx.

Important Note – Patient Education on Medication and Medical Warnings

Practices should be aware that the Medication and Medical Warning data displayed to a patient on the ManageMyHealth portal will change post activation of BPACNZRx. As Medications and Medical Warnings are re-mapped from the MIMS drug formulary to its equivalent in the NZF drug formulary the updated record will be uploaded to the patient's record on ManageMyHealth. A patient may query the change in the Medication names or Medical Warning names, and as such a practice may need to consider patient education around these changes.

Important Note - Request Repeat Prescription (RRP) Messages

If a patient has requested a repeat of their Medications which includes existing MIMS Medications and Medical Warnings that are yet to be mapped and converted to NZF Medications and Medical Warnings, the provider will be prompted with the Drug Mapping and/or Medical Warning screens during the Repeat Medication process. The provider will be required to complete the remapping processes before the Request Repeat Prescription (RRP) process can be completed. However, as it is assumed repeating medications should not introduce clinical risks this step can be optionally bypassed in the interest of time.

PHO Clinical Event Export

Clinical Performance Indicators - Statins

Utilities ► LinkTech ► PHO Clinical Event

The PHO Clinical Event Export will continue to function after activation of BPACNZRx.

The 'CVD risk recorded as >= 15%, prescribed statins' query performed as part of the PHO Clinical Event Export has been updated to ensure that both MIMS and NZF statin drugs are considered as part of the data collection.

Specifically for NZF, the inclusion of drugs that have an ATC Code which STARTS with C10AA or C10BA or equal to A10BH51.

New Zealand ePrescribing Service

Module ► Clinical ► Patient ePrescriptions

The New Zealand ePrescribing Service will continue to function after activation of BPACNZRx.

Pharmac SA

Utilities ► Pharmac SA ► Pharmac SA

The Pharmac Special Authorities submission will continue to function after activation of BPACNZRx.

Prescribing Assistant

Module ► Clinical ► New Prescription

All medications for which Prescribing Assistant is triggered under the MIMS drug formulary (e.g. Dabigatran) will continue to function after activation of BPACNZRx.



Are you looking for a quick answer to your support query or changes related to this release?

Sara, our Virtual Support Chat Bot is available within our Insight Customer Portal 24 hours a day, 7 days a week, whenever you need help.

All you need to do is type a question, and Sara will provide the answer. She has been trained on most of the questions we get asked regularly on our Support Desk.

If Sara cannot answer your support query, she will assist you in creating a Support Ticket or can pass you onto a member of our Customer Care team.

If you would like to ask Sara your next support query, log into Insight at insight.medtechglobal.com